Table 2.
Final predictive factors for diarrhea and rash derived from the dataset
| Variablea | Odds ratio | (95 %CI)b | Impact relative risk |
|---|---|---|---|
| Predictors for grade ≥ 2 diarrhea | |||
| Patient age | 1.03 | (1.0–1.06) | ↑ by 3 % for each year |
| Each additional cycle | 0.88 | 0.80–0.95) | ↓ by 12 % per cycle |
| Skin metastases at baseline | 0.29 | (0.11–0.73) | ↓ by 71 % |
| Grade I diarrhea in prior cycle | 2.0 | (0.98–4.3) | ↑ two fold |
| Therapy started in the spring | 2.1 | (1.2–3.6) | ↑ two fold |
| Predictors for grade ≥ 2 rash | |||
| Planned dose of capecitabine/cycle (grams) | 1.03 | (0.99–1.08) | ↑ by 3 % with each gram |
| Brain metastases at baseline | 6.0 | (0.97–37.6) | ↑ 6 fold |
| Concomitant use of 5HT3 antiemetics | 25.4 | (11–59) | ↑ 25 fold |
aThese are the final variables that were retained following the application of the Likelihood ratio test (p < 0.05 to retain) in a backwards elimination process
b95 %CI determined by nonparametric bootstrapping